ArticleERJ open research2018
Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma.
Article in ERJ open research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease Areas.Advances in therapy · 2025Pooled it
- Evidence for similarity in symptoms and mechanism: The extra-pulmonary symptoms of severe asthma and the polysymptomatic presentation of fibromyalgia.Immunity, inflammation and disease · 2019Trial
- Strategies and Behaviour Change Techniques to Optimise Sedentary Behaviour for People with Severe Asthma: A Nominal Group Technique.Journal of clinical medicine · 2026Article
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- Integrating hot topics and implementation of treatable traits in asthma.The European respiratory journal · 2024Review
- Burden and unmet needs in asthma care in the Asia-Pacific region.Public health challenges · 2022Article
- What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance.ERJ open research · 2021Article
- The Patients' Experience of Severe Asthma Add-On Pharmacotherapies: A Qualitative Descriptive Study.Journal of asthma and allergy · 2021Article
- Perspectives on decisions for treatment and care in severe asthma.The World Allergy Organization journal · 2021Review
- Living well with severe asthma.Breathe (Sheffield, England) · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a large global survey, Still Fighting for Breath, in patients with severe persistent asthma, 10 years after the Fighting for Breath survey to assess the impact of disease on patients' lives and to determine if control and management have changed in recent years. Data were collected from 1333 adults (aged >18 years) and caregivers of children (aged 6-17 years) with severe persistent asthma from nine countries through an online survey conducted in 2016 by GfK. A decade after the first survey, our results showed that the impact of severe asthma has not changed significantly and a high proportion of patients with severe asthma remain inadequately controlled. A large discrepancy was observed between the proportion of patients who perceived their asthma to be well controlled (42%) and the proportion of patients who reported to be well controlled as per the Global Initiative for Asthma (GINA) assessment (6%). Although most patients perceived their asthma to be controlled, many experienced frequent symptoms that affected their daily lives. Thus, there is a need for improved management (support and strategies) of patients with severe persistent asthma and improved coordination of efforts that would enable these patients to achieve better disease control.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.